A comparison of the tolerability and efficacy of lovastatin 20 mg and fluvastatin 20 mg in the treatment of primary hypercholesterolemia

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 1, Issue 2, 1996, Pages 101-106

  Berger, Marc L ^a   Wilson, Helene M ^a   Liss, Charles L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

High density lipoproteins; Low density lipoproteins; Risk strata

Indexed keywords

EID: 0000139084     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/107424849600100203     Document Type: Article

References (8)

1. National Cholesterol Education Program, Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Institutes of Health, Bethesda, MD, Publication No. 93-3095, 1993.
2. Hlingworth DR, Tobert JA. A review of clinical trials comparing HMG CoA reductase inhibitors. Clin Therapeut 16:366, 1994.
3. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 18:499, 1972.
4. Oster G. Borok GM, Mensin J.et al.A randomized trial to assess effectiveness and cost in clinical practice: Rationale and design of the cholesterol-reduction intervention study (CRIS). Controlled Clinical Trials 16:3, 1995.
5. Hunninghake DB, Stein EA, Dujovne CA,et al.The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med 328:1213, 1993.
6. Bradford RH, Shear CL, Chremos AN,et al.Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia. Am J Med 91:18S, 1991.
7. Desylperc JP. The role of HMG CoA reductase inhibitors in the treatment of hypcrlipidemia: A review of fluvastatin. Current Ther 56:111, 1995.
8. Betteridge DJ, Durrington PN, Fairhurst GJ,et al.Comparison of lipid-lowering effects of low dose fluvastatin and conventional dose gemfibrozil in patients with primary hypercholesterolemia. Am J Med 96(Suppl 6A):45, 1994.